154 related articles for article (PubMed ID: 19490067)
1. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa.
Eichinger S; Lubsczyk B; Kollars M; Traby L; Zwiauer K; Gleiss A; Quehenberger P; Kyrle PA
Eur J Clin Invest; 2009 Aug; 39(8):707-13. PubMed ID: 19490067
[TBL] [Abstract][Full Text] [Related]
2. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium.
Mauser-Bunschoten EP; de Goede-Bolder A; Wielenga JJ; Levi M; Peerlinck K
Neth J Med; 1998 Dec; 53(6):249-55. PubMed ID: 9883002
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
4. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
Bakhtiari K; Kamphuisen PW; Mancuso ME; Hamulyak K; Schutgens RE; Santagostino E; Meijers JC
Br J Haematol; 2013 Sep; 162(6):827-35. PubMed ID: 23889493
[TBL] [Abstract][Full Text] [Related]
5. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
Bhat V; von Drygalski A; Gale AJ; Griffin JH; Mosnier LO
Thromb Haemost; 2016 Mar; 115(3):551-61. PubMed ID: 26466980
[TBL] [Abstract][Full Text] [Related]
6. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
7. The role of factor VII in haemostasis: infusion studies of factor VIIa in a canine model of factor VIII deficiency.
Mertens K; Briët E; Giles AR
Thromb Haemost; 1990 Aug; 64(1):138-44. PubMed ID: 2274919
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor VIIa does not induce hypercoagulability in vitro.
Gallistl S; Cvirn G; Muntean W
Thromb Haemost; 1999 Feb; 81(2):245-9. PubMed ID: 10064000
[TBL] [Abstract][Full Text] [Related]
9. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
[TBL] [Abstract][Full Text] [Related]
10. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects.
Friederich PW; Levi M; Bauer KA; Vlasuk GP; Rote WE; Breederveld D; Keller T; Spataro M; Barzegar S; Büller HR
Circulation; 2001 May; 103(21):2555-9. PubMed ID: 11382723
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution.
Ovanesov MV; Panteleev MA; Sinauridze EI; Kireev DA; Plyushch OP; Kopylov KG; Lopatina EG; Saenko EL; Ataullakhanov FI
Blood Coagul Fibrinolysis; 2008 Dec; 19(8):743-55. PubMed ID: 19002040
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
[TBL] [Abstract][Full Text] [Related]
13. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
Hay CR; Negrier C; Ludlam CA
Thromb Haemost; 1997 Dec; 78(6):1463-7. PubMed ID: 9423795
[TBL] [Abstract][Full Text] [Related]
14. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors.
Majumdar G; Savidge GF
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1031-3. PubMed ID: 8148476
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa.
Carr ME; Martin EJ; Kuhn JG; Ambrose H; Fern S; Bryant PC
Clin Lab; 2004; 50(9-10):529-38. PubMed ID: 15481628
[TBL] [Abstract][Full Text] [Related]
16. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
[TBL] [Abstract][Full Text] [Related]
17. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
Martinowitz U; Livnat T; Zivelin A; Kenet G
Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
[TBL] [Abstract][Full Text] [Related]
18. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF
Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351
[TBL] [Abstract][Full Text] [Related]
19. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
[TBL] [Abstract][Full Text] [Related]
20. Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction.
Livnat T; Sehgal A; Qian K; Van Nguyen H; Madigan K; Sorensen B; Kenet G
Blood Cells Mol Dis; 2020 May; 82():102416. PubMed ID: 32066048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
